Back to search results

Cognitive Training for Hematopoietic Cell Transplant Survivors

This study is looking at whether an online program called Lumosity can help improve thinking and memory skills (cognitive function) in people who have had a hematopoietic cell transplant (HCT), a type of bone marrow transplant. It also wants to understand how patients feel about getting information on their genetic risk for cognitive problems after HCT. You might be able to join if you are at least 21 years old, 3 to 6 months post-HCT at UAB, speak English, and have internet access at home. The study will measure how many people complete the program and how their cognitive function changes over 12 weeks. The current status of this study is unclear.

Study design
This is a randomized study with 60 participants. Some participants will start the Lumosity program right away, while others will wait 12 weeks.
What's involved
If you participate, you would use the Lumosity program daily for 12 weeks, completing 5 training tasks per session.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured at 12 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03094026

Cognitive Training Intervention and Attitudes Towards Genetics

Recruiting
NAAges 21+InterventionalSupportive care
University of Alabama at Birmingham
~60 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:LumosityLumosity (waitlist control)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of HCT patients completing the 2-arm wait-listed randomized trial of cognitive training intervention for a period of 3 months
Measured over 12 weeks
+1 more outcome measured

Conditions

Cognitive Impairment
Hematologic Neoplasms
Hematopoietic Cell Transplant

Explore related trials

Cognitive DysfunctionHematologic Neoplasm

NCT03094026

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Alabama at Birmingham

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Noha M Sharafeldin · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham

Who to contact

Noha M Sharafeldin, MD,MSc, PhD
[email protected]
2056382144
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥ 21 years old at time of allogeneic HCT performed at UAB
Outpatient and between 3 and 6 months post HCT
English speaking
Possess access to an internet-connected home computer

Exclusion

History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments
Participated in neuropsychological intervention within the past 6 months
History of color blindness

What this trial measures

  • Number of HCT patients completing the 2-arm wait-listed randomized trial of cognitive training intervention for a period of 3 months12 weeks

    Number of participants completing the 12 week intervention

  • Change in cognitive function between intervention and wait list control arms from baseline to 12 weeks.Baseline to 12 weeks

    Change in cognitive function will be measured using cognitive test scores at baseline and 12 weeks